Quoin Pharmaceuticals announces additional 'whole body' clinical data from ongoing Pediatric Netherton syndrome study and approval to initiate testing of a second pediatric patient ($0.21, 0.00)
Quoin Pharmaceuticals files U.S. patent application for topical formulations to treat Netherton Syndrome and other skin diseases ($0.30, 0.00)
Quoin Pharmaceuticals reports Q4 EPS ($0.35) vs FactSet ($0.46) [3 est, ($0.51)-(0.43)] ($0.30, 0.00)
Quoin Pharmaceuticals files US and international patent applications for novel topical rapamycin formulations ($0.30, 0.00)
Quoin Pharmaceuticals announces 'whole body' clinical data from ongoing pediatric Netherton Syndrome study ($0.31, 0.00)
Quoin Pharmaceuticals announces further clinical evidence of QRX003 effectiveness in Netherton Syndrome ($0.59, 0.00)
Quoin Pharmaceuticals announces further clinical data from ongoing Pediatric Netherton Syndrome study ($0.57, 0.00)
Quoin Pharmaceuticals announces additional interim data from ongoing open-label Netherton Syndrome clinical study ($0.70, 0.00)
Quoin Pharmaceuticals prices $6.8M public offering at $0.45 per share through Maxim Group ($0.65, 0.00)
Quoin Pharmaceuticals announces FDA clearance to initiate new QRX003 Netherton syndrome clinical study ($0.56, 0.00)
Powered by FactSet Research Systems Inc.